



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 19TH DECEMBER 2018
AT 12.30pm**

**IN PHARMACY SEMINAR ROOM, PHARMACY DEPARTMENT,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2018/178: APOLOGIES:

Dr T Mackenzie (TM)	GP, EL CCG
---------------------	------------

2018/179: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2018/180: MINUTES OF NOVEMBER MEETING:

Accepted as a correct record.

2018/181: MATTERS ARISING:

2018/052: LMMG Recommendations (from Feb LMMG) - Melatonin guidelines –
ongoing - LR/JV/CD to suggest updated wording to clarify point 3 on page 7 in the
transition to adult services section. VG then to follow up with specialist.

2018/073: Rifaxamin – Guidelines for Prescribing – amended document to include comments from gastro, treatment for most continues beyond 6 months included. Accepted by ELMMB for use in ELHE and upload to website.

2018/164: Dry Eye Drops Including New Product Requests – VisuXL®, Systane Balance®, Clinitas Multi® - further information being prepared by ophthalmology. Defer discussion until they can attend ELMMB meeting.

2018/167: LMMG Recommendation from Oct – Headache Management Pathway – comments have been fed back to LMMG and guideline updated accordingly.

2018/169: Formulary Updates: Levosert® IUD (levonorgestrel) – for use as cost effective alternative to Mirena for most patients. Training will be provided. Levosert® added to formulary.

2018/182: NEW PRODUCT REQUEST – FLEXITOL® 25% UREA HEEL BALM & 10% UREA CREAM

Flexitol® requested by Dr M Littley, Consultant Diabetologist. The 25% Urea Heel Balm is for the treatment of callus on heels and feet in diabetic patients and then to maintain hydration of feet with 10% urea cream. The 10% urea cream can also be used for dry skin in other areas.

Resolved: Flexitol® 25% Urea Heel Balm approved for addition to formulary for diabetic patients and Flexitol® 10% urea cream to replace Eucerin® cream on formulary.
Traffic Light: Green

2018/183: LMMG CONSULTATIONS (for Jan LMMG)

Asthma guidelines – the summary flow chart was considered useful but would like some amendments to include further information as per comments from respiratory review group. The local ELHE product information would still be required.

Cannabis based medicinal products for pain Position Statement – ELMMB supports the position statement.

Out of Area Prescribing Policy – Discussion suggested the tables included were too complicated. The information on green and amber isn't necessary. The information for black and red traffic light medicines is a priority with a clear position statement to reflect this. In the box on page 3 an additional point for local decision could be included. Addition of a sample letter to send to requestor was suggested as an appendix.

Resolved: Comments to be sent to LMMG

2018/184: LMMG RECOMMENDATIONS (from Nov LMMG)

Testosterone Shared Care Guideline – the document is supported as a temporary measure until a more comprehensive review of the evidence is undertaken. This will ensure any current prescribing is done in accordance with appropriate monitoring highlighted in the shared care document. It was suggested that a pathway for when testosterone is appropriate would be helpful. LR has requested that LMMG conduct a

comprehensive review of the clinical evidence. CD to forward examples of existing pathways.

Combined Adult & Child ADHD Shared Care Guideline – accepted as written for use in ELHE.

Psoriasis: Biologic & High Cost Drug Commissioning Pathway – updated - accepted as written for use in ELHE.

2018/185: FORMULARY UPDATES

Adcal D3 – defer to next meeting, LR to provide ELHT with details of proposed product to consider.

Amgevita – this is the brand of Adalimumab biosimilar that this area has been allocated to use. It is the citrate free preparation. Add to formulary.

Resolved: Formulary to be updated as above

2018/186: RMOG LIOTHYRONINE GUIDANCE

Currently liothyronine has a black traffic light in ELHE. The RMOG guidance suggests it may be appropriate in exceptional circumstances. In such cases an IFR application can be made. Based on the lack of clinical evidence, members agreed liothyronine remains Black in ELHE.

Resolved: Liothyronine to remain black traffic light.

2018/187: NUTRITIONAL SUPPLEMENTS IN SUBSTANCE MISUSERS - UPDATE

The following sentence has been added - Long term use should be ONLY following dietician assessment and continued ONLY under active dietitian review.

2018/188: NICE RECOMMENDATIONS (from Nov)

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545) is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Padeliporfin for untreated localised prostate cancer [TA546] is not recommended by NICE. **Traffic Light: BLACK**

Tofacitinib for moderately to severely active ulcerative colitis (TA547) is recommended as an option by NICE. Approved in line with NICE.
CCG Commissioned – Blueteq form required **Traffic Light: RED**

STANDING ITEMS

2018/189: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Nov 2018

Minutes acknowledged

2018/190: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Oct 2018

Minutes acknowledged

Dates of future meetings discussed – to remain as 3rd Wednesday of the month but to start at 12 noon.

DATE OF NEXT MEETING – Wednesday 16th January 2019 12.00noon, Seminar Room 6, Learning & development Centre, RBH

Dates for 2019: All 3rd Wednesday of the month starting at 12 noon

16th January
20th February
20th March
17th April
15th May
19th June
17th July
21st August
18th September
16th October
20th November
18th December

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 19TH DECEMBER 2018

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2018/052	LMMG Recommendations (from Feb LMMG) Melatonin guidelines – suggest wording to clarify transitional information. Follow up with specialists	LR/JV/CD	Nov 18
		VG	Nov 18
2018/164	Dry Eye Drops Including New Product Requests – VisuXL®, Systane Balance®, Clinitas Multi® - further information being prepared by ophthalmology to discuss.	CW	Jan 19